When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Montelukast - Wikipedia

   en.wikipedia.org/wiki/Montelukast

   Montelukast, sold under the brand name Singulair among others, is a medication used in the maintenance treatment of asthma. [6] It is generally less preferred for this use than inhaled corticosteroids. [6] It is not useful for acute asthma attacks. [6] Other uses include allergic rhinitis and hives of long duration. [6]

3. If You're Living With Asthma, Here's Every Single Treatment ...

   www.aol.com/youre-living-asthma-heres-every...

   Here’s a fun fact: Ninety percent of people with asthma will develop symptoms of exercise-induced asthma as well, but 10 percent of people with this condition (also referred to as exercise ...

4. Anti-asthmatic agent - Wikipedia

   en.wikipedia.org/wiki/Anti-asthmatic_agent

   An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...

5. Tedral - Wikipedia

   en.wikipedia.org/wiki/Tedral

   Asthma is a chronic condition that affects the airways in the lungs. The image shows the difference between a healthy bronchial airway (left) and a bronchial airway during an asthma attack (right). Exposure to asthma triggers can lead to inflammation and narrowing of airways in asthma patients, resulting in asthma attacks and breathing ...

6. Long-acting beta-adrenoceptor agonist - Wikipedia

   en.wikipedia.org/wiki/Long-acting_beta...

   The proposed mechanism is that while LABAs relieve asthma symptoms, they can also promote bronchial inflammation and sensitivity without warning. [23] On February 18, 2011, the FDA issued a safety alert for long-acting β agonists. [24]

7. Dexpramipexole - Wikipedia

   en.wikipedia.org/wiki/Dexpramipexole

   EXHALE-4: [7] a global Phase III clinical trial to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma, is currently recruiting people ≥12 years old with a documented physician diagnosis of asthma who require treatment with at least low-dose inhaled corticosteroids and one other ...